Humacyte
Manufacturing · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2525 E North Carolina Hwy 54, Durham, No...Phone Number
(919) 313-9633Website
www.humacyte.comRevenue
<$5 MillionStock Symbol
HUMAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Explore more
Humacyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Humacyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Humacyte
Click to see if Humacyte had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Humacyte has new funding data
Product Launch: Get notified when Humacyte launches new products
Check if Humacyte has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Humacyte recently announced quarterly report
Check out if Humacyte is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Humacyte, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Humacyte
Find 2 more new buyers
Compare Similar Companies to Humacyte
Compare insights from companies similar to Humacyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Humacyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Humacyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Humacyte.
Humacyte financials insights
Gather financial insights about Humacyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series B
$150M
2016
Private Equity
$10M
2017
Unspecified
$14.1M
2018
Other Financing Round
$150M
2020
Debt
$2M
2021
Debt
$50M
2023
Debt
$150M
Humacyte Tech Stack
A closer look at the technologies used by Humacyte
See more technologies
Most Recent Scoops
Person-Based
Finance, Financial Transactions
Project
Humacyte has entered into a $1.475 million purchase commitment with the Kingdom of Saudi Arabia to facilitate clinical evaluation and outreach programs for Symvess in hospitals within the kingdom, conducted in parallel with ongoing negotiations with a kingdom-based entity for a joint venture and license to commercialize Symvess in-country.
Business Development, Clinical Operations
Layoffs
Humacyte has announced the layoffs of approximately 45 employees, representing roughly 25% of its workforce, in May 2026 as part of a workforce restructuring effort to reduce costs, enabled by the successful completion of multiple technical and clinical projects.
Layoffs, Clinical Operations
Executive Move
Humacyte has announced that Dr. Todd Rasmussen has been named Chief Surgical Officer at Humacyte. Dr. Rasmussen is recognized as a pioneer in modern vascular surgery, particularly in vascular trauma and peripheral artery disease.
Executive Move
Humacyte News & Media
Humacyte CMO tax sell-to-cover of 45,887 shares | HUMA Insider Trading - Stock Titan
Humacyte CMO Shamik Parikh reports automated sale of 45,887 shares at $0.8967 to cover tax on RSU vesting, retaining 272,713 shares afterward.Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals –Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer -Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Humacyte
Sign Up For FreeTo access detailed company insights
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ves... Read More
